Inventor · disambiguated record
Bhavnish Parikh
Also filed as: PARIKH BHAVNISH · PARIKH BHAVNISH VINOD
17 granted patents·8 pending applications·254 citations·filing 1997–2025
95Inventor score
Top patents by PatentIndex Score
25 records- 0197US11337927B2Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2020·Granted May 24, 2022·12 cites·34 claims
- 0297US11219624B2Topical formulation for a JAK inhibitorINCYTE CORP·Filed 2020·Granted Jan 11, 2022·10 cites·12 claims
- 0397US10874616B2Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2018·Granted Dec 29, 2020·17 cites·36 claims
- 0497US10869870B2Topical formulation for a JAK inhibitorINCYTE CORP·Filed 2020·Granted Dec 22, 2020·10 cites·29 claims
- 0596US10166191B2Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2013·Granted Jan 1, 2019·32 cites·12 claims
- 0695US11590136B2Topical formulation for a JAK inhibitorINCYTE CORP·Filed 2022·Granted Feb 28, 2023·2 cites·27 claims
- 0795US11045421B2Sustained release dosage forms for a JAK1 inhibitorINCYTE CORP·Filed 2020·Granted Jun 29, 2021·11 cites·48 claims
- 0895US10758543B2Topical formulation for a JAK inhibitorINCYTE CORP·Filed 2019·Granted Sep 1, 2020·14 cites·20 claims
- 0994US11571425B2Topical formulation for a JAK inhibitorINCYTE CORP·Filed 2022·Granted Feb 7, 2023·2 cites·28 claims
- 1094US9655854B2Sustained release dosage forms for a JAK1 inhibitorINCYTE CORP·Filed 2014·Granted May 23, 2017·55 cites·31 claims
- 1192US10561616B2Sustained release dosage forms for a JAK1 inhibitorINCYTE CORP·Filed 2017·Granted Feb 18, 2020·15 cites·18 claims
- 1290US12226419B2Topical formulation for a JAK inhibitorINCYTE HOLDINGS CORP·Filed 2024·Granted Feb 18, 2025·0 cites·20 claims
- 1390US2025064746A1Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2024·Application pending·0 cites
- 1487US2025312279A1Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2025·Application pending·0 cites
- 1586US11896717B2Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2022·Granted Feb 13, 2024·0 cites·23 claims
- 1685US2023277541A1Topical formulation for a jak inhibitorINCYTE CORP·Filed 2022·Application pending·0 cites
- 1784US5948437APharmaceutical compositions using thiazepineZENECA LTD·Filed 1997·Granted Sep 7, 1999·74 cites·15 claims
- 1884US2025127724A1Sustained release dosage forms for a jak1 inhibitorINCYTE CORP·Filed 2024·Application pending·0 cites
- 1983US11576865B2Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2022·Granted Feb 14, 2023·0 cites·30 claims
- 2082US11576864B2Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2022·Granted Feb 14, 2023·0 cites·30 claims
- 2180US2022211631A1Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2022·Application pending·0 cites
- 2279US2022211707A1Topical formulation for a jak inhibitorINCYTE CORP·Filed 2021·Application pending·0 cites
- 2374US12151026B2Sustained release dosage forms for a JAK1 inhibitorINCYTE CORP·Filed 2021·Granted Nov 26, 2024·0 cites·18 claims
- 2460US2015250790A1Topical formulation for a jak inhibitorINCYTE CORP·Filed 2015·Application pending·0 cites
- 2559US2011288107A1Topical formulation for a jak inhibitorPARIKH BHAVNISH·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Bhavnish Parikh files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →